- Home
- URGN vs EHAB Comparison
URGN vs EHAB Comparison
Compare URGN & EHAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- EHAB
- Stock Information
- Founded
- URGN 2004
- EHAB 2014
- Country
- URGN United States
- EHAB United States
- Employees
- URGN N/A
- EHAB N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- EHAB Hospital/Nursing Management
- Sector
- URGN Health Care
- EHAB Health Care
- Exchange
- URGN Nasdaq
- EHAB Nasdaq
- Market Cap
- URGN 465.9M
- EHAB 405.4M
- IPO Year
- URGN 2017
- EHAB N/A
- Fundamental
- Price
- URGN $9.67
- EHAB $7.68
- Analyst Decision
- URGN Strong Buy
- EHAB Hold
- Analyst Count
- URGN 7
- EHAB 3
- Target Price
- URGN $37.21
- EHAB $8.50
- AVG Volume (30 Days)
- URGN 499.1K
- EHAB 311.6K
- Earning Date
- URGN 05-12-2025
- EHAB 05-07-2025
- Dividend Yield
- URGN N/A
- EHAB N/A
- EPS Growth
- URGN N/A
- EHAB N/A
- EPS
- URGN N/A
- EHAB N/A
- Revenue
- URGN $90,398,000.00
- EHAB $1,034,800,000.00
- Revenue This Year
- URGN $38.65
- EHAB $5.33
- Revenue Next Year
- URGN $118.69
- EHAB $4.86
- P/E Ratio
- URGN N/A
- EHAB N/A
- Revenue Growth
- URGN 9.29
- EHAB N/A
- 52 Week Low
- URGN $8.94
- EHAB $6.85
- 52 Week High
- URGN $20.70
- EHAB $10.70
- Technical
- Relative Strength Index (RSI)
- URGN 41.45
- EHAB 34.58
- Support Level
- URGN $8.94
- EHAB $7.56
- Resistance Level
- URGN $10.83
- EHAB $7.91
- Average True Range (ATR)
- URGN 0.79
- EHAB 0.35
- MACD
- URGN -0.07
- EHAB -0.08
- Stochastic Oscillator
- URGN 29.67
- EHAB 9.42
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.